Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher M Rubino

Showing results (11-20 of 68) with videos related to

Pageof 7
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 14, 2010
Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditisSujata M Bhavnani, Christopher M Rubino, Paul G Ambrose, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2002
Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study TeamRonald N Jones, Christopher M Rubino, Sujata M Bhavnani, et al.
Antibiotics (Basel, Switzerland)|July 19, 2020
Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and ThriveM Courtney Safir, Sujata M Bhavnani, Christine M Slover, et al.
Antimicrobial Agents and Chemotherapy|November 9, 2016
Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against ItselfPaul G Ambrose, Brian VanScoy, Haley Conde, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2015
Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit ConsiderationsSujata M Bhavnani, Paul G Ambrose, Jeffrey P Hammel, et al.
Advances in Therapy|August 16, 2017
A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult VolunteersLin Pan, Paula Belloni, Han Ting Ding, et al.
Antimicrobial Agents and Chemotherapy|August 16, 2021
Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric PatientsChristopher M Rubino, Anthony P Cammarata, Anne Smits, et al.
The Pediatric Infectious Disease Journal|January 1, 2015
Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of AgeJohn S Bradley, Sailaja Puttagunta, Christopher M Rubino, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2025
Population pharmacokinetic analyses for telavancin using data from healthy subjects and patients with infectionsScott A Van Wart, M Courtney Safir, Sujata M Bhavnani, et al.
Diagnostic Microbiology and Infectious Disease|June 28, 2008
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumoniaSujata M Bhavnani, Alan Forrest, Jeffrey P Hammel, et al.
Pageof 7

Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 14, 2010
Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditisSujata M Bhavnani, Christopher M Rubino, Paul G Ambrose, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2002
Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study TeamRonald N Jones, Christopher M Rubino, Sujata M Bhavnani, et al.
Antibiotics (Basel, Switzerland)|July 19, 2020
Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and ThriveM Courtney Safir, Sujata M Bhavnani, Christine M Slover, et al.
Antimicrobial Agents and Chemotherapy|November 9, 2016
Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against ItselfPaul G Ambrose, Brian VanScoy, Haley Conde, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2015
Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit ConsiderationsSujata M Bhavnani, Paul G Ambrose, Jeffrey P Hammel, et al.
Advances in Therapy|August 16, 2017
A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult VolunteersLin Pan, Paula Belloni, Han Ting Ding, et al.
Antimicrobial Agents and Chemotherapy|August 16, 2021
Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric PatientsChristopher M Rubino, Anthony P Cammarata, Anne Smits, et al.
The Pediatric Infectious Disease Journal|January 1, 2015
Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of AgeJohn S Bradley, Sailaja Puttagunta, Christopher M Rubino, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2025
Population pharmacokinetic analyses for telavancin using data from healthy subjects and patients with infectionsScott A Van Wart, M Courtney Safir, Sujata M Bhavnani, et al.
Diagnostic Microbiology and Infectious Disease|June 28, 2008
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumoniaSujata M Bhavnani, Alan Forrest, Jeffrey P Hammel, et al.
Pageof 7